Risdiplam

利司扑兰

Report date: 2023/12/14 17:55:40
NME

Base Information

Drug NameRisdiplam
Drug Alias NameEVRYSDI艾满欣RG-7916RO-7034067
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionSurvival motor neuron protein modulators
TargetsSurvival motor neuron protein
Therapy Area/IndicationsMuscular Atrophy, Spinal
Global Approved IndicationsMuscular Atrophy, Spinal
Approved Indications in ChinaMuscular Atrophy, Spinal
Original Approved Country/TerritoryUnited States
Original Approved Date2020/08/07
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPtc Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdPtc Therapeutics IncF. Hoffmann-La Roche Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsMuscular Atrophy, Spinal
Inactive IndicationsN/A

Other Information

ATC CodeM09A
Related LinksN/A